EMPOWER: Using Patient and Breast Cancer Disease Characteristics to Direct Combination Therapy in the Treatment of Metastatic HRPositive, HER2-Negative Breast Cancer

 
Wednesday, February 20, 2019
6:00 PM – 8:30 PM

Location

JW Marriott Marquis Miami
255 Biscayne Blvd. Way
Miami, FL 33131
Meeting Room: Junior Ballroom

 

REGISTER NOW!
Already Registered?
SIGN IN

 
 

WEBCAST DATE

Wednesday, February 20, 2019

6:00 PM Eastern    5:00 PM Central    4:00 PM Mountain    3:00 PM Pacific

Add to Calendar 02/20/2019 06:00 PM 02/20/2019 08:30 PM America/New_York EMPOWER: Using Patient and Breast Cancer Disease Characteristics to Direct Combination Therapy in the Treatment of Metastatic HRPositive, HER2-Negative Breast Cancer EMPOWER: Using Patient and Breast Cancer Disease Characteristics to Direct Combination Therapy in the Treatment of Metastatic HRPositive, HER2-Negative Breast Cancer Live Simulcast Med Learning Group info@medlearninggroup.com false MM/DD/YYYY atZOdzeAgzXtBkKLjmOo27579

 

PROGRAM FEATURES

  • Virtual reality animation
  • Create your own Personalized Poster Online Portal
  • iPads provided to enhance learning experience

FACULTY

Joyce O’Shaughnessy, MD
Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Texas Oncology
US Oncology Network
Dallas, TX

Mohammad Jahanzeb, MD, FACP
Professor of Clinical Medicine, Hematology-Oncology
Medical Director, USylvester Deerfield Beach
Associate Director of Community Outreach
University of Miami
Miami, FL

AGENDA

I. Targeting uncontrolled cellular proliferation: drivers of the cell cycle
  A. Estrogen receptor-positive breast cancer
    • Estrogen receptor and its role in breast cancer pathogenesis
    • Signaling pathways disruption and PI3K/mTOR axis
    • Dysregulation of the cell cycle - cyclin D1- CDK 4/6/axis
      i. Effects on the cell cycle; CDK cell-cycle regulation and intracellular messengers (eg, Rb, E2F)
  B. CDK 4/6 inhibitors – differential effects across CDK 4/6 pathway
    • Profile of mechanisms of action
      i. Pharmacodynamics and pharmacokinetics

II. Optimizing CDK 4/6 inhibition in the patient with advanced breast cancer
  A. Profiling the patient who is a candidate for CDK 4/6 inhibition
    • Patients who are treatment naïve or previously treated – 1st line or 2nd line of therapy
    • Response to prior therapy, metastatic sites
    • Patient’s medical history and CDK 4/6 AE profile
    • Prognostic markers and their interpretation

III. CDK 4/6 clinical trials data and their application to oncology practice
  A. Cyclin-dependent kinase 4/6 inhibitors
    • Review the clinical trials data - efficacy and safety in advanced and metastatic disease
    • 1st-line and 2nd-line therapy – treatment options
    • Treatment and management considerations for associated adverse events - Patient factors and tolerability - Monitoring required while on treatment
  B. Anti-estrogen therapy
    • Recent clinical trial results
    • In combination with CDK 4/6 inhibition or monotherapy?

IV. Multidisciplinary oncology team - educational and decision-making strategies for the oncology patient
  A. Educational strategies for the oncology patient
    • Disease state, medication use – dosing regimen (how and when to take, persistence/adherence, dosing options), potential adverse events and their management, review of treatment plan
    • Shared decision-making in the care process – use of decision aids
  B. Oral oncolytic medication – use and side-effect management
    • Importance of adherence and persistence for successful treatment and recognition and reporting of adverse events to healthcare
    • Healthcare providers - answer questions regarding potential drug-drug interactions with patient’s concurrent medications
    • Ongoing, routine communication throughout treatment

V. Case study video and review

VI. Question and answer

LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

  • Describe the involvement of CDKs and cyclins in the uncontrolled cellular proliferation characteristic of breast cancer
  • Review how to use patient and disease characteristics to identify the individual with advanced, HR+ breast cancer who would benefit from the use of CDK 4/6 inhibition
  • Analyze the properties of CDK 4/6 inhibitors and the potential pharmacodynamic effects in patients with hormone receptor positive, HER2-negative advanced breast cancer
  • Discuss the application of CDK 4/6 inhibitor clinical trial data to the management of breast cancer patients in a community oncology practice
  • Explain the patient’s and healthcare team’s responsibilities that will foster a multidisciplinary effort to optimize outcomes

TARGET AUDIENCE

This CME initiative is designed to meet the educational needs of medical oncologists, nurse practitioners, nurses, pharmacists, and other healthcare providers involved in the treatment of patients with hormone receptor-positive, HER2-negative advanced breast cancer.

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
 
 

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this live activity for a maximum of 2.5 AMA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with Breast Cancer.

CNE Credits: 2.5 ANCC Contact Hour(s)

CNE Accreditation Statement:

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 2.5 contact hour(s) of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact: Med Learning Group at info@medlearninggroup.com.

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: http://www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc.). Please contact Med Learning Group prior to the live event at info@medlearninggroup.com

Feel free to pass this invitation on to your physicians, fellows, physician assistants, nurses, pharmacists, healthcare practitioners, and any other colleagues that you believe would be interested in attending this free CME/CNE program.

 

WEBCAST REGISTRATION

Please use the following form to register for this webcast. You will receive an email confirmation shortly after you complete the registration.

If you are unable to register online or do not receive your confirmation email after registering, please email us at support@performedia.com.

Registration Form


*Required field

WEBCAST SIGNIN

Please enter your registered email and click the Sign In button to watch the Live Simulcast.

If you are unable to sign in or watch the live simulcast, please email us at support@performedia.com.

 

 

 

Copyright © 2019 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.